drugset / Trial / NCT05832047

Aggressive Hydration With Lactated Ringer's Solution Versus Plasma Solution for the Prevention of Post ERCP Pancreatitis

NCT05832047 ↗

Phase 4 Completed 844 enrolled Do Hyun Park HK inno.N Corporation · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

In the existing Aggressive hydration comparison study related to the prevention of post-ERCP pancreatitis (PEP), research bias may occur due to the lack of blinding between fluids, so in this study, the investigators will conduct a multicenter randomized comparative study in which the comparative fluids are double-blinded to observe differences between fluids in the preventive effect of pancreatitis that occurs after ERCP (endoscopic retrograde cholangiopancreatography). A total of 844 patients scheduled for ERCP will be enrolled in this clinical trial and randomly assigned to the lactated Ringer's solution or to the Plasma solution in a 1:1 ratio. Eligible patients will receive study drug or control drug for up to 24 hours before and after ERCP implementation. In previous comparative studies related to PEP prevention, research bias may have been introduced because of insufficient blinding of the treatment strategies, as well as instances where the evaluating investigator did not perform blinding. We are therefore conducting a multicenter, randomized comparative study double-blinded as to the two types of fluid (lactated Ringer's solution or plasma solution), and in which the endoscopists, outcome assessors and patients are blinded to the randomization allocation.

Timeline

Start
2023-06-19
Primary completion
2024-07-25
Completion
2025-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Plasma solution Unknown 3 unknown Intravenous
Comparator lactated Ringer's solution Unknown 3 unknown Intravenous

Indications